Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Benigno Rodriguez

Showing results (101-110 of 137) with videos related to

Pageof 14
Sort By:
Journal of Acquired Immune Deficiency Syndromes (1999)|February 7, 2014
Factors associated with delayed hepatitis B viral suppression on tenofovir among patients coinfected with HBV-HIV in the CNICS cohortH Nina Kim, Carla V Rodriguez, Stephen Van Rompaey, et al.
AIDS (London, England)|October 15, 2020
Substantial decline in heavily treated therapy-experienced persons with HIV with limited antiretroviral treatment optionsKristina L Bajema, Robin M Nance, Joseph A C Delaney, et al.
AIDS (London, England)|June 6, 2013
Association of early HIV viremia with mortality after HIV-associated lymphomaSatish Gopal, Monita R Patel, Elizabeth L Yanik, et al.
Pathogens & Immunity|November 4, 2017
Prospective Analysis of Lipid Composition Changes with Antiretroviral Therapy and Immune Activation in Persons Living with HIVMartha A Belury, Emily Bowman, Janelle Gabriel, et al.
The Journal of Infectious Diseases|September 16, 2011
Immunologic failure despite suppressive antiretroviral therapy is related to activation and turnover of memory CD4 cellsMichael M Lederman, Leonard Calabrese, Nicholas T Funderburg, et al.
The Lancet. HIV|September 15, 2015
A Randomized, Double-Blind, Placebo-Controlled Clinical Trial of a Chemokine Receptor 5 (CCR5) Antagonist to Decrease the Occurrence of Immune Reconstitution Inflammatory Syndrome in HIV-Infection: The CADIRIS StudyJuan G Sierra-Madero, Susan Ellenberg, Mohammed S Rassool, et al.
Plos Pathogens|June 5, 2010
Perforin expression directly ex vivo by HIV-specific CD8 T-cells is a correlate of HIV elite controlAdam R Hersperger, Florencia Pereyra, Martha Nason, et al.
BMJ Open|March 22, 2020
Antiretroviral drug class and anaemia risk in the current treatment era among people living with HIV in the USA: a clinical cohort studyBarbara N Harding, Bridget M Whitney, Robin M Nance, et al.
Blood|April 17, 2013
The immunologic effects of maraviroc intensification in treated HIV-infected individuals with incomplete CD4+ T-cell recovery: a randomized trialPeter W Hunt, Nancy S Shulman, Timothy L Hayes, et al.
The Lancet. HIV|October 2, 2015
Effect of the CCR5 antagonist maraviroc on the occurrence of immune reconstitution inflammatory syndrome in HIV (CADIRIS): a double-blind, randomised, placebo-controlled trialJuan G Sierra-Madero, Susan S Ellenberg, Mohammed S Rassool, et al.
Pageof 14

Showing results (101-110 of 137) with videos related to

Sort By:
Pageof 14
Journal of Acquired Immune Deficiency Syndromes (1999)|February 7, 2014
Factors associated with delayed hepatitis B viral suppression on tenofovir among patients coinfected with HBV-HIV in the CNICS cohortH Nina Kim, Carla V Rodriguez, Stephen Van Rompaey, et al.
AIDS (London, England)|October 15, 2020
Substantial decline in heavily treated therapy-experienced persons with HIV with limited antiretroviral treatment optionsKristina L Bajema, Robin M Nance, Joseph A C Delaney, et al.
AIDS (London, England)|June 6, 2013
Association of early HIV viremia with mortality after HIV-associated lymphomaSatish Gopal, Monita R Patel, Elizabeth L Yanik, et al.
Pathogens & Immunity|November 4, 2017
Prospective Analysis of Lipid Composition Changes with Antiretroviral Therapy and Immune Activation in Persons Living with HIVMartha A Belury, Emily Bowman, Janelle Gabriel, et al.
The Journal of Infectious Diseases|September 16, 2011
Immunologic failure despite suppressive antiretroviral therapy is related to activation and turnover of memory CD4 cellsMichael M Lederman, Leonard Calabrese, Nicholas T Funderburg, et al.
The Lancet. HIV|September 15, 2015
A Randomized, Double-Blind, Placebo-Controlled Clinical Trial of a Chemokine Receptor 5 (CCR5) Antagonist to Decrease the Occurrence of Immune Reconstitution Inflammatory Syndrome in HIV-Infection: The CADIRIS StudyJuan G Sierra-Madero, Susan Ellenberg, Mohammed S Rassool, et al.
Plos Pathogens|June 5, 2010
Perforin expression directly ex vivo by HIV-specific CD8 T-cells is a correlate of HIV elite controlAdam R Hersperger, Florencia Pereyra, Martha Nason, et al.
BMJ Open|March 22, 2020
Antiretroviral drug class and anaemia risk in the current treatment era among people living with HIV in the USA: a clinical cohort studyBarbara N Harding, Bridget M Whitney, Robin M Nance, et al.
Blood|April 17, 2013
The immunologic effects of maraviroc intensification in treated HIV-infected individuals with incomplete CD4+ T-cell recovery: a randomized trialPeter W Hunt, Nancy S Shulman, Timothy L Hayes, et al.
The Lancet. HIV|October 2, 2015
Effect of the CCR5 antagonist maraviroc on the occurrence of immune reconstitution inflammatory syndrome in HIV (CADIRIS): a double-blind, randomised, placebo-controlled trialJuan G Sierra-Madero, Susan S Ellenberg, Mohammed S Rassool, et al.
Pageof 14